Impact of Dexamethasone Responsiveness on Long Term Outcome in Patients with Newly Diagnosed Multiple Myeloma

Dexamethasone (Dex), alone or in combination, is commonly used for treating multiple myeloma. Dex as single agent for initial therapy of myeloma results in overall response rates of 50-60%. It is unclear whether steroid responsiveness reflects any biological characteristic that impacts long-term out...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Sinha, Shirshendu, Rajkumar, S. Vincent, Lacy, Martha Q., Hayman, Suzanne R., Buadi, Francis K., Dispenzieri, Angela, Dingli, David, Kyle, Robert A., Gertz, Morie A., Kumar, Shaji
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2009
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2864312/
https://ncbi.nlm.nih.gov/pubmed/19958361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.08023.x
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge